Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | PANK3 | Q9H999 | 8/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.51 |
| ▸ | SMO | Q99835 | 3/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14844043 | 0.84 | SMO (0.56) | KDM4EALDH1A1L3MBTL1PANK3SMO | |
| SCHEMBL29514660 | 0.84 | KDM4E (0.54) | KDM4EALDH1A1L3MBTL1PANK3SMO | |
| SCHEMBL3048925 | 0.84 | KDM4E (0.54) | KDM4EALDH1A1L3MBTL1PANK3SMO | |
| SCHEMBL3592248 | 0.83 | PANK3 (0.53) | KDM4EALDH1A1L3MBTL1PANK3SMO | |
| SCHEMBL2322911 | 0.83 | HTR3A (0.47) | ALDH1A1L3MBTL1PPARGPANK3HRH4 | |
| SCHEMBL578498 | 0.83 | HTR3A (0.47) | KDM4EALDH1A1L3MBTL1PPARGHRH4 | |
| SCHEMBL4287978 | 0.83 | DRD2 (0.53) | KDM4EALDH1A1L3MBTL1PANK3SMO | |
| SCHEMBL3051541 | 0.83 | CNR2 (0.54) | KDM4EALDH1A1L3MBTL1PANK3SMO | |
| SCHEMBL2828952 | 0.83 | SMO (0.53) | KDM4EALDH1A1L3MBTL1PANK3SMO | |
| SCHEMBL1743219 | 0.83 | PANK3 (0.56) | KDM4EALDH1A1L3MBTL1PANK3SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | claimed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | claimed |
| EP-2121598-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-11-25 | — | — | EP | claimed |
| WO-2008076754-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2008-06-26 | — | — | WO | claimed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
| CN-110467629-B | Benzoquinone derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-04-25 | — | — | US | disclosed |
| WO-2018125961-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | MITOBRIDGE, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
| WO-2017160670-A1 | M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2009053373-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-30 | — | — | WO | disclosed |
| EP-1308439-B1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1950199-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008076754-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2008-06-26 | — | — | WO | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-6462047-B1 | CONTAINING 5- OR 6-MEMBERED OXYGEN, NITROGEN AND/OR SULFUR HETEROARYL GROUP; ANGINA, HYPERTENSION, RESPIRATORY DISTRESS, CONGESTIVE HEART FAILURE, RENAL FAILURE, ATHEROSCLEROSIS, INFLAMMATORY DISEASES, STROKES, BRONCHITIS, ASTHMA | ICOS CORPORATION | 2002-10-08 | — | — | US | disclosed |
| EP-1114048-A1 | CARBOLINE DERIVATIVES AS CGMP PHOSPHODIESTERASE INHIBITORS | Bombrun, Agnès (FR) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015639-A1 | CARBOLINE DERIVATIVES AS CGMP PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CA | KDM4E 3334/4885ALDH1A1 1354/4885L3MBTL1 3805/4885 |
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | KDM4E 2261/4885ALDH1A1 2818/4885L3MBTL1 3780/4885 |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | KDM4E 2567/4885ALDH1A1 3638/4885L3MBTL1 4442/4885 |
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | KDM4E 1763/4885ALDH1A1 2743/4885L3MBTL1 4596/4885 |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | KDM4E 1763/4885ALDH1A1 2743/4885L3MBTL1 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.